tbuckley/cabot-search huggingface dataset:
JAK2 L884P Mutation Confers Resistance To The Type II JAK2 Inhibitor NVP-BBT594 When Co-Occurring With JAK2 R683G But Not JAK2 V617F
Authors: Nadja Kopp, Jordy C. Van der Zwet, Jacob Layer, Oliver Weigert, Eric Vangrevelinghe, Akinori Yoda, Thomas Radimerski, David Weinstock
Journal: Blood (2013)
MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase–mediated suppression of histone deacetylase 2
Authors: Richard Y. Kim, Jay C. Horvat, James W. Pinkerton, Malcolm R. Starkey, Ama T. Essilfie, Jemma R. Mayall, Prema M. Nair, Nicole G. Hansbro, Bernadette Jones, Tatt Jhong Haw, Krishna P. Sunkara, Thi Hiep Nguyen, Andrew G. Jarnicki, Simon Keely, Joerg Mattes, Ian M. Adcock, Paul S. Foster, Philip M. Hansbro
Journal: Journal of Allergy and Clinical Immunology (2016)
Laser lithotripsy with a standard endoscope through a hepaticoduodenostomy
Authors: Amy Tyberg, Kunal Karia, Amit Desai, Steven Zerbo, Dong Kim, Reem Sharaiha, Michel Kahaleh
Journal: Endoscopy (2015)

Advanced techniques are often required for the removal of large biliary stones, impacted stones, and intrahepatic stones because traditional endoscopic retrograde cholangiopancreatography (ERCP) is insufficient for extraction [1] [2].
Circulating Progenitor Cells Identify Peripheral Arterial Disease in Patients With Coronary Artery Disease
Authors: Salim S. Hayek, James MacNamara, Ayman S. Tahhan, Mosaab Awad, Adithya Yadalam, Yi-An Ko, Sean Healy, Iraj Hesaroieh, Hina Ahmed, Brandon Gray, Salman S. Sher, Nima Ghasemzadeh, Riyaz Patel, Jinhee Kim, Edmund K. Waller, Arshed A. Quyyumi
Journal: Circulation Research (2016)

Rationale: Peripheral arterial disease (PAD) is a clinical manifestation of extracoronary atherosclerosis. Despite sharing the same risk factors, only 20% to 30% of patients with coronary artery disease (CAD) develop PAD. Decline in the number of bone marrow–derived circulating progenitor cells (PCs) is thought to contribute to the pathogenesis of atherosclerosis. Whether specific changes in PCs differentiate patients with both PAD and CAD from those with CAD alone is unknown. Objective: Determine whether differences exist in PCs counts of CAD patients with and without known PAD. Methods and Results: 1497 patients (mean age: 65 years; 62% men) with known CAD were identified in the Emory Cardiovascular Biobank. Presence of PAD (n=308) was determined by history, review of medical records, or imaging and was classified as carotid (53%), lower extremity (41%), upper extremity (3%), and aortic disease (33%). Circulating PCs were enumerated by flow cytometry. Patients with CAD and PAD had significantly lower PC counts compared with those with only CAD. In multivariable analysis, a 50% decrease in cluster of differentiation 34 (CD34+) or CD34+/vascular endothelial growth factor receptor-2 (VEGFR2+) counts was associated with a 31% ( P =0.032) and 183% ( P =0.002) increase in the odds of having PAD, respectively. CD34+ and CD34+/VEGFR2+ counts significantly improved risk prediction metrics for prevalent PAD. Low CD34+/VEGFR2+ counts were associated with a 1.40-fold (95% confidence interval, 1.03–1.91) and a 1.64-fold (95% confidence interval, 1.07–2.50) increases in the risk of mortality and PAD-related events, respectively. Conclusions: PAD is associated with low CD34+ and CD34+/VEGFR2+ PC counts. Whether low PC counts are useful in screening for PAD needs to be investigated.
Measles Outbreak Associated with Vaccine Failure in Adults — Federated States of Micronesia, February–August 2014
Authors: Lucy Breakwell, Edna Moturi, Louisa Helgenberger, Sameer V. Gopalani, Craig Hales, Eugene Lam, Umid Sharapov, Maribeth Larzelere, Eliaser Johnson, Carolee Masao, Eleanor Setik, Lisa Barrow, Samantha Dolan, Tai-Ho Chen, Minal Patel, Paul Rota, Carole Hickman, William Bellini, Jane Seward, Greg Wallace, Mark Papania
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

On May 15, 2014, CDC was notified of two laboratory-confirmed measles cases in the Federated States of Micronesia (FSM), after 20 years with no reported measles. FSM was assisted by the World Health Organization (WHO), the United Nations Children’s Fund (UNICEF), and CDC in investigating suspected cases, identify contacts, conduct analyses to guide outbreak vaccination response, and review vaccine cold chain practices. During February–August, three of FSM’s four states reported measles cases: Kosrae (139 cases), Pohnpei (251), and Chuuk (3). Two thirds of cases occurred among adults aged ≥20 years; of these, 49% had received ≥2 doses of measles-containing vaccine (MCV). Apart from infants aged <12 months who were too young for routine vaccination, measles incidence was lower among children than adults. A review of current cold chain practices in Kosrae revealed minor weaknesses; however, an absence of historical cold chain maintenance records precluded an evaluation of earlier problems. Each state implemented vaccination campaigns targeting children as young as age 6 months through adults up to age 57 years. The preponderance of cases in this outbreak associated with vaccine failure in adults highlights the need for both thorough case investigation and epidemiologic analysis to guide outbreak response vaccination. Routine childhood vaccination coverage achieved in recent years limited the transmission of measles among children. Even in areas where transmission has not occurred for years, maintaining high 2-dose MCV coverage through routine and supplemental immunization is needed to prevent outbreaks resulting from increased measles susceptibility in the population.
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Authors: Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi, Yukiyasu Okamura, Masaru Konishi, Ippei Matsumoto, Yuji Kaneoka, Yasuhiro Shimizu, Shoji Nakamori, Hirohiko Sakamoto, Soichiro Morinaga, Osamu Kainuma, Koji Imai, Naohiro Sata, Shoichi Hishinuma, Hitoshi Ojima, Ryuzo Yamaguchi, Satoshi Hirano, Takeshi Sudo, Yasuo Ohashi
Journal: The Lancet (2016)
AB0028 The Abnormal CD4+T Lymphocyte Subset Distribution Shown by Naïve Rheumatoid Arthritis Patients Can be Modulated by Methotrexate Treatment
Authors: C. Bohόrquez, L. Ruiz, C. Garcia, A. Gόmez-La Hoz, A. Turriόn, H. Moruno, A. Pérez, A.I. Sánchez, E. Cuende, A. Movasat, F. Albarrán, M.J. Leόn, D. Díaz, J. Monserrat, M. Άlvarez-Mon
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Mechanisms regulating the chronic autoimmune response in rheumatoid arthritis (RA) are not well understood. However, activated T CD4+ play a pivotal role initiating and perpetuating the chronic inflammation characteristic for the disease. <h3>Objectives</h3> Evaluate the number and distribution of circulating CD4+ T lymphocytes and their CD4+ naïve T cells (T<sub>N</sub>), central memory (T<sub>CM</sub>), non-terminated effector memory (T<sub>NTEM</sub>) and terminated effector memory (T<sub>TEM</sub>) T cells subsets in a population of recently diagnosed DMARD naive RA patients before and along the first 6 months of methotrexate (MTX) treatment. <h3>Methods</h3> The number of circulating CD4+ T lymphocytes, and of their T<sub>N</sub>, TM, TCM and TEM subsets in fifty untreated patients with RA before MTX treatment and at 3 and 6 months of treatment were assayed using a multiparametric flow cytometry. We also studied twenty-four age- and sex-matched healthy subjects as controls. <h3>Results</h3> RA naïve patients show a significant (p&lt;0.05) expansion of the circulating CD4+ T<sub>NTEM</sub> subset. MTX non responder naïve RA patients show from basal conditions a significative expansion of CD4+ T<sub>NTEM</sub> lymphocytes and develop significant expansion of CD4+ T<sub>CM</sub>, and CD4+ T<sub>EM</sub> lymphocyte subsets along MTX treatment. <h3>Conclusions</h3> Recently diagnosed DMARD naive RA patients show involvement of the circulating CD4+ T lymphocytes activation/differentiation stage subsets. MTX treatment show immunomodulatory effects on CD4+ T lymphocyte compartment with different behavior in responder and non-responder patients. <h3>Disclosure of Interest</h3> None declared
HIV-related symptoms and psychological functioning in a cohort of homosexual men
Authors: D G Ostrow, A Monjan, J Joseph, M VanRaden, R Fox, L Kingsley, J Dudley, J Phair
Journal: American Journal of Psychiatry (1989)

The authors administered the Center for Epidemiological Studies Depression (CES-D) Scale to 4,954 homosexual men in the Multicenter AIDS Cohort Study. HIV antibody status at enrollment was a less important predictor of psychological distress than were reported physical symptoms. Multivariate analysis showed an association between a high score on each CES-D Scale component and the number of self-reported possible AIDS- or HIV-related symptoms, perceived lymphadenopathy, and absence of "someone to talk to about serious problems." This relationship between self-reported physical symptoms and psychological distress suggests a possible etiologic relationship between perceived AIDS risk and psychological symptoms in men at risk of AIDS.
Controlled trial of zimelidine, a 5-HT reuptake inhibitor, for treatment of depression
Authors: A Georgotas, M Krakowski, S Gershon
Journal: American Journal of Psychiatry (1982)

The authors conducted a double-blind, placebo-controlled clinical trial of the selective 5-HT reuptake inhibitor zimelidine in the treatment of major depressive illness. Zimelidine had the same antidepressant efficacy as amitriptyline but significantly fewer side effects, especially anticholinergic effects.
Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine
Authors: Talha Badar, Gloria Mattiuzzi, Hagop M Kantarjian, Farhad Ravandi, Naval G. Daver, Guillermo Garcia Manero, Tapan M. Kadia, Elias J. Jabbour, Gautam Borthakur, Jorge E. Cortes
Journal: Blood (2013)
Effect of visual inspection with acetic acid (VIA) screening by primary health workers on cervical cancer mortality: A cluster randomized controlled trial in Mumbai, India.
Authors: Surendra Srinivas Shastri, Indraneel Mittra, Gauravi Mishra, Subhadra Gupta, Rajesh Dikshit, Rajendra A. Badwe
Journal: Journal of Clinical Oncology (2013)

2 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
Protection and Reactivation of Cardioglobulin-A by High Energy Phosphate Compounds
Authors: EDWARD J. LEONARD, STEPHEN HAJDU
Journal: Circulation Research (1964)

The biological activity of cardioglobulin-A can be destroyed enzymatically by a short equilibration with homogenates prepared from a wide variety of tissues. Blood plasma alone also contains a cardioglobulin-A inactivating system which is stimulated by the removal or dilution of an unidentified small molecule normally present in the plasma. Inactivation of cardioglobulin-A can be prevented by the addition of certain high energy phosphate compounds, notably ATP, ADP or CP . Furthermore, the biological activity of inactivated cardioglobulin-A can frequently be restored by addition of CP. When the whole cardioglobulin system acts on the frog heart, cardioglobulin-A activity is gradually depleted. This is associated with a loss of protein-bound phosphorus from a component of the mixture. Activity can be restored by addition of CP . It has been proposed that the action of the cardioglobulin system involves the release of bound cardioglobulin-C calcium. A possible role of cardioglobulin-A may be to provide, through a ∼ P linkage, the energy for the release of this calcium.
Cognitive function and the dexamethasone suppression test in depression
Authors: E D Caine, B I Yerevanian, K A Bamford
Journal: American Journal of Psychiatry (1984)

Twenty patients with major depressive disorder defined by the Research Diagnostic Criteria were given a range of neuropsychological tests and evaluated with the dexamethasone suppression test (DST). No correlation was found between results on the DST and cognitive impairment.
Comparative analysis of pathway proteins in cancer cells in primary and metastatic tumors and circulating tumor cells.
Authors: B. Ybarrondo, S. Bruckner, S. Hornyak, E. Webster, T. Lee, P. S. Kim, S. Singh
Journal: Journal of Clinical Oncology (2011)

e11132 Background: Changes in the tumor biomarker status between primary site and metastatic lesions are known to occur at a significant frequency. Correlating biomarker status in primary and metastatic tumors as well as circulating tumor cells (CTCs) may provide critical information for overall diseases pathogenesis. Here we report correlative profiling of tumor cells obtained from metastatic regions and CTCs to primary disease. Methods: The Collaborative Enzyme Enhanced Reactive-immunoassay (CEER) is a multiplexed protein microarray platform requiring co-localization of two detector enzyme-conjugated-antibodies. In this study, fine needle aspirate (FNA) samples were collected from various metastatic sites (lymph nodes, lung, liver, chest well, etc.) from 58 breast cancer (BCA) patients and matching CTCs for correlative analysis of HER1, HER2, p95HER2, HER3, cMET, cKIT, IGF-1R, PI3K, AKT, ERK and other pathway proteins for their expression/activation. Results: Using the CEER assay, a comprehensive profile of pathway proteins can be determined from limited amounts of cancer cells in FNAs taken from metastatic sites. HER2 expression and activation was shown to be the primary pathway in some patients; however, a significant subset of HER2 positive patients also showed expression/activation of other redundant pathway proteins such as HER3, cMET, and IGF1R as well as truncated HER2 (p95HER2). Expression/activation of other targetable pathway proteins were found in BCA-FNAs with no HER2 activity. Varying levels of HER2 expression/activation were found in CTCs. The concordance of HER2 status between primary tumor, metastatic-FNAs and CTCs will be presented when samples IDs are un-blinded. Conclusions: The sensitivity and specificity of CEER assay is sufficient to provide a single-cell-level target phosphorylation. This enables profiling of pathway proteins in samples with limited amount of tumor cells, allowing frequent monitoring of tumor profile during the course of the treatments. Determination of comprehensive pathway analysis is critical in selecting the most effective therapy options and overcoming potential drug resistance through treatment combination or sequencing.
Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.
Authors: James Hsieh, David Chen, Patricia Wang, Yingbei Chen, Almedina Redzematovic, Mahtab Marker, Parul Patel, Michael Chevinsky, Umeshkumar Bhanot, Patrizia Pinciroli, Nancy Bouvier, Kety H. Huberman, Michael F. Berger, Nicholas D. Socci, Emily Cheng, William Lee, Jennifer J. Knox, Martin Henner Voss, Maurizio Voi, Robert Motzer
Journal: Journal of Clinical Oncology (2015)

4509 Background: Several large genomic analyses of RCC have recently identified prevalent mutations in epiegenetic regulators with prognostic significance. However, the impact of these novel mutations on clinical outcomes of different classes of targeted therapies is unknown. We explored the potential correlations between somatic mutations and treatment efficacy in RECORD-3, a randomized phase 2 trial comparing 1st-line everolimus (EVE) then sunitinib (SUT) with 1st-line SUT then EVE at progression in 471 treatment-naïve mRCC patients (pts)(JCO 32:2764-72). Methods: Somatic mutations in exons of 341 cancer related genes were identified by an NGS assay (MSK IMPACT platform) at ~530X coverage on tumor (archival tissues, 260 pts) and matched germline (181 pts) DNA. Association between genotypes and 1stline PFS was assessed by Cox PH models and log-rank tests. Results: PBRM1 mutations were associated with longer PFS within EVE (median PFS [mPFS] 11.1 vs 5.3 months; unadjusted p=0.0031). Pts with PBRM1 mutations (41% of the cohort) derived comparable PFS benefit from EVE vs. SUT. KDM5C mutations were associated with longer PFS within SUT (mPFS 20.6 vs 8.4 months; unadjusted p=0.0511). Profiles of 227 clear cell RCC (ccRCC) pts showed a SETD2 mutation rate of 29%, substantially higher than the 10% seen in random tumor sample cohorts (842 pts, Nature Genetics 45:849-50), suggesting SETD2’s role in ccRCC metastasis. Conclusions: Mutations in epigenetic regulators PBRM1 and KDM5C may represent novel mechanisms associated with sensitivity to EVE or SUT. These candidate predictive biomarkers could be considered as molecular entry criteria for prospective clinical studies in selecting mTORC1 or VEGFR inhibitors for genomically distinct mRCC pts. Clinical trial information: NCT00903175. Genes Genotype EVE SUT Hazard Ratio (95% CI) events/ pts mPFS (95% CI) months events/ pts mPFS (95% CI) months RAD/SUT PBRM1 MT 35 / 49 11.5 (8.1, 16.2) 41 / 57 11.0 (8.4, 13.4) 1.07 (0.66, 1.74) PBRM1 WT 64 / 79 5.3 (3.1, 8.3) 48 / 75 8.3 (7.1, 13.9) 1.85 (1.25, 2.75) KDM5C MT 10 / 11 9.8 (2.2, 16.6) 11 / 21 20.6 (12.4, 27.3) 2.35 (0.96, 5.72) WT 89 / 117 8.1 (5.4, 10.5) 78 / 111 8.4 (8.1, 11.3) 1.38 (1.00, 1.90)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Authors: Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, Emma C. Scott, Ahmad Halwani, Martin Gutierrez, Michael M. Millenson, Adam D. Cohen, Stephen J. Schuster, Daniel Lebovic, Madhav Dhodapkar, David Avigan, Bjoern Chapuy, Azra H. Ligon, Gordon J. Freeman, Scott J. Rodig, Deepika Cattry, Lili Zhu, Joseph F. Grosso, M. Brigid Bradley Garelik, Margaret A. Shipp, Ivan Borrello, John Timmerman
Journal: Journal of Clinical Oncology (2016)

Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence has emerged in hematologic malignancies.In this phase I, open-label, dose-escalation, cohort-expansion study, patients with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma received the anti-PD-1 monoclonal antibody nivolumab at doses of 1 or 3 mg/kg every 2 weeks. This study aimed to evaluate the safety and efficacy of nivolumab and to assess PD-L1/PD-L2 locus integrity and protein expression.Eighty-one patients were treated (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; multiple myeloma, n = 27). Patients had received a median of three (range, one to 12) prior systemic treatments. Drug-related adverse events occurred in 51 (63%) patients, and most were grade 1 or 2. Objective response rates were 40%, 36%, 15%, and 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively. Median time of follow-up observation was 66.6 weeks (range, 1.6 to 132.0+ weeks). Durations of response in individual patients ranged from 6.0 to 81.6+ weeks.Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.
Ongoing measles outbreak in Elche, Spain, 29 January to 9 March 2012
Authors: J A Delgado de los Reyes, M Arencibia Jiménez, J F Navarro Gracia, E Alonso Echabe, P García Puente, E M Banqueri Guerrero, G Pérez Torregrosa, J D Calle Barreto, R Zurriaga Carda
Journal: Eurosurveillance (2012)

On 29 January 2012, the first case of measles in Elche, Spain, since 2001 was notified through the epidemiological surveillance system of the Valencian Community. As of 9 March, 109 cases have been notified. The outbreak started in a neighbourhood where the vaccination coverage of the population is inadequate. This report highlights the need to vaccinate the susceptible population and also points to the importance of developing coordinated measures between public health centres and hospital preventive services.
Fainting on exposure to phobic stimuli
Authors: G C Curtis, B Thyer
Journal: American Journal of Psychiatry (1983)

Two patients with phobias for medical procedures and trauma developed "vasovagal syncope" with hypotension and bradycardia while viewing a videotape of a venous cutdown. Eleven hours of exposure therapy per patient eliminated both the phobic and fainting responses. These facts support existing hypotheses that phobias of this type and vasovagal fainting are associated and that vasovagal syncope is a diphasic response. They do not support hypotheses that vasovagal syncope follows sudden cessation of anxiety, that that counter-conditioning is necessary for successful treatment, or that novel symptoms emerge following behavioral treatment of these phobias.
High alcoholism rate in patients with essential tremor
Authors: D Schroeder, H A Nasrallah
Journal: American Journal of Psychiatry (1982)

The authors reviewed the charts of 36 patients discharged from a VA medical center with a diagnosis of essential tremor over a 10-year period for evidence of alcohol dependency or abuse and for family history of alcoholism and other psychiatric disorders. A sex- and age-matched sample of patients admitted during the same period for herniorrhaphy was used as a control group. Patients with essential tremor had a significantly higher frequency of alcohol dependence and abuse than control subjects and also had a much higher rate of positive first-degree family history of alcoholism. The authors suggest that essential tremor is an important cause of secondary alcoholism.
Heterotopic gastric mucosa mimicking a rectal submucosal tumor
Authors: Yuyong Tan, Yongjun Wang, Deliang Liu
Journal: Endoscopy (2015)

A 61-year-old man came to our hospital with a 4-year history of intermittent tenesmus. There was no family history of rectal carcinoma. Upon presentation, his physical examination was remarkable only for a soft mass on the posterior wall of the rectum. Laboratory studies showed a positive fecal occult blood test but no other test abnormalities. Colonoscopy revealed a protrusive lesion, 10 mm in diameter, located about 5 cm away from the anal verge ([Fig. 1]). Endoscopic ultrasound (EUS) showed that the mass was originating from the submucosal layer ([Fig. 2]).